VIDEO: The 3-D structure of the protein complex of SOCS1 (red) and JAK1 (beige) explains how SOCS1 ‘swtiches off’ signalling and could underpin the development of new cancer treatments. view more
Walter and Eliza Hall Institute researchers have visualised for the first time how the protein SOCS1 ‘switches off’ cell signalling to dampen immune responses and block cancer growth.
The atomic-level structure of SOCS1 binding to its partner protein JAK could guide the development of drugs that alter disease-causing cell signalling pathways, and may have applications for treating some blood cancers, including leukaemias.
The research, led by Dr Nick Liau, Dr Nadia Kershaw, Associate Professor Jeff Babon and Professor Nick Nicola, was published in the journal Nature Communications.
AT A GLANCE
– The SOCS1 protein binds to JAK proteins to ‘switch off’ cell signalling, which dampens processes including immune responses and cancer growth.
– Our researchers have used structural biology to visualise how SOCS1 binds to JAK proteins in never-before seen detail.
– The detailed structure may guide the development of new drugs that modify JAK activity, amplifying or dampening cell responses, with potential applications in cancer therapies.
SWITCHING OFF SIGNALLING
Dr Liau said the structure of the protein
Article originally posted at